Stock markets in India are trading higher taking cues from their Asian peers, which rebounded today following a strong lead in Wall Street. The gains came after a Thursday rebound in US markets, with a string of positive news ranging from strong corporate earnings to reports of a revival in US-China trade talks all boosting investor sentiment. Gains are largely seen in healthcare stocks and metal stocks.
The BSE Sensex is trading up by 300 points and the NSE Nifty is trading up by 89 points. Meanwhile, the BSE Mid Cap index is trading up by 0.8% while, the BSE Small Cap index is trading up by 0.9%. The rupee is currently trading at 70.23 to the US$.
In news from the pharma sector. As per an article in a leading financial daily, AstraZeneca Pharma India has received Import & Market permission for olaparib (Lynparza) 100 mg and 150 mg tablets in India by the Drug Controller General of India (DCGI).
The receipt of this permission paves way for the launch of olaparib (Lynparza) in India, subject to the receipt of further related statutory approvals and licenses.
For ovarian cancer, olaparib is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy.
AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. For breast cancer, olaparib is indicated for patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.
Speaking of the pharma sector, the BSE Healthcare Index has been on a roller coaster ride in the past few years. The period from 2012 to 2015 saw the index go up more than three times.
